Therefore, considering the emerging and motivating results using these approaches to treat BC, we believe that BCG delivery using NPs functionalized with monoclonal antibodies, in particular anti-EGFR, will provide a significantly improved delivery system for treatment of human BC. This evidence concerns the gene EGFR and breast cancer.